| dc.contributor.author | YAZICI, H | |
| dc.contributor.author | HAMURYUDAN, V | |
| dc.contributor.author | YURDAKUL, S | |
| dc.date.accessioned | 2021-03-05T16:53:55Z | |
| dc.date.available | 2021-03-05T16:53:55Z | |
| dc.date.issued | 1995 | |
| dc.identifier.citation | YAZICI H., YURDAKUL S., HAMURYUDAN V., "BEHCETS-SYNDROME - HOW SHOULD WE TREAT IT", CLINICAL IMMUNOTHERAPEUTICS, cilt.3, ss.102-107, 1995 | |
| dc.identifier.issn | 1172-7039 | |
| dc.identifier.other | av_c2d4d241-ae8a-4c53-b71c-8fa423b02e79 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/129305 | |
| dc.identifier.uri | https://doi.org/10.1007/bf03259272 | |
| dc.description.abstract | Behcet's syndrome is a multisystem vasculitis of unknown aetiology. Eye involvement, the main cause of morbidity, can lead to blindness in 20% of those affected. Other lesions, ranging from aphthous and genital ulceration to sometimes fatal central nervous system involvement, also cause considerable morbidity and, we have become more recently aware, mortality. | |
| dc.language.iso | eng | |
| dc.subject | Temel Bilimler | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Yaşam Bilimleri | |
| dc.subject | Eczacılık | |
| dc.subject | Temel Eczacılık Bilimleri | |
| dc.subject | Farmakoloji ve Toksikoloji | |
| dc.subject | FARMAKOLOJİ VE ECZACILIK | |
| dc.subject | Yaşam Bilimleri (LIFE) | |
| dc.subject | İmmünoloji | |
| dc.title | BEHCETS-SYNDROME - HOW SHOULD WE TREAT IT | |
| dc.type | Makale | |
| dc.relation.journal | CLINICAL IMMUNOTHERAPEUTICS | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 3 | |
| dc.identifier.issue | 2 | |
| dc.identifier.startpage | 102 | |
| dc.identifier.endpage | 107 | |
| dc.contributor.firstauthorID | 116013 | |
